Data / Form D filings / Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc.: Form D filings
Viracta Subsidiary, Inc., a biotechnology company in Cardiff, CA, filed 11 Form D notices with the SEC between 2010 and 2021. The latest, on March 10, 2021, reports $65 million sold of a $65 million offering to 26 investors.
Find out what Viracta Subsidiary, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 2533 S. Coast Highway 101, Suite 210, Cardiff, CA, 92007
- Phone
- (858) 771-4190
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1416377
The full lists. Form D filings in California: 5,891 rows, $138.91, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 10, 2021 | New notice | $64,999,994 | $64,999,994 | $0 | 26 | Feb 24, 2021 | sec.gov |
| Dec 10, 2020 | New notice | $40,000,000 | $39,999,997 | $3 | 14 | Nov 25, 2020 | sec.gov |
| Nov 5, 2019 | New notice | $24,999,999 | $16,774,987 | $8,225,012 | 21 | Oct 24, 2019 | sec.gov |
| Feb 12, 2019 | New notice | $5,714,363 | $5,714,363 | $0 | 25 | Jan 31, 2019 | sec.gov |
| Feb 12, 2019 | Amendment | $10,695,495 | $10,695,495 | $0 | 6 | Nov 30, 2018 | sec.gov |
| Dec 13, 2018 | New notice | $10,000,000 | $2,000,000 | $8,000,000 | 1 | Nov 30, 2018 | sec.gov |
| Jul 2, 2018 | New notice | $8,500,000 | $2,685,000 | $5,815,000 | 27 | Jun 18, 2018 | sec.gov |
| Apr 5, 2017 | New notice | $26,875,622 | $9,875,623 | $16,999,999 | 9 | Mar 23, 2017 | sec.gov |
| Apr 4, 2012 | New notice | $16,000,000 | $6,499,999 | $9,500,001 | 10 | Mar 7, 2012 | sec.gov |
| Aug 2, 2010 | Amendment | $16,124,045 | $16,064,150 | $59,895 | 12 | Jan 19, 2010 | sec.gov |
| Feb 1, 2010 | New notice | $12,651,233 | $5,999,999 | $6,651,234 | 5 | Jan 19, 2010 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Ivor Royston | Executive Officer, Director | |
| Richard Ghalie | Director | |
| Michael Huang | Director | |
| Daniel Chevallard | Executive Officer | |
| Roger Pomerantz | Director | |
| Gur Roshwalb | Director | |
| Samuel Murphy | Director |
Other biotechnology companies in California that filed recently
- CARI Health, Inc. $280,000 · Nov 6, 2026
- Ausel, Inc. $120,000 · Nov 4, 2026
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
- Tempest Therapeutics, Inc. $7.5 million · Oct 14, 2026
- Lionheart Health, Inc. $387,500 · Oct 7, 2026
- Rakuten Medical, Inc. $9 million · Oct 6, 2026
- Zonaliz, Inc. $2.5 million · Oct 5, 2026
- Altay Therapeutics, Inc. $15.7 million · Oct 2, 2026
- Sialia Therapeutics, Inc. $1.5 million · Sep 29, 2026
- Vetmab Biosciences, Inc. $11.4 million · Sep 29, 2026
Every Form D from the week of Mar 8, 2021 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Viracta Subsidiary, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.